EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access

Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients

Rachael K Ross iD, Edward V Nunes iD, Mark Olfson, Matisyahu Shulman iD, Noa Krawczyk iD, Elizabeth A Stuart, Kara E Rudolph iD

Addiction · 2024

DOI: 10.1111/add.16630 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Addiction, 2024. Verfasst von Rachael K Ross und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Naltrexone, Delayed-Action Preparations, Buprenorphine. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse of the National Institutes of Health, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Extended‐release naltrexone (XR‐NTX) and sublingual buprenorphine (SL‐BUP) are both approved for opioid use disorder (OUD) treatment in any medical setting. We aimed to compare the real‐world effectiveness of XR‐NTX and SL‐BUP. Design and setting This was an observational active comparator, new user cohort study of Medicaid claims records for patients in New Jersey and California, USA, 2016–19. Participants/cases The participants were adult Medicaid patients aged 18–64 years who initiated XR‐NTX or SL‐BUP for maintenance treatment of OUD and did not use medications for OUD in the 90 days before initiation. Our cohort included 1755 XR‐NTX and 9886 SL‐BUP patients.

Measurements

We examined two outcomes up to 180 days after medication initiation: (1) composite of medication discontinuation and death and (2) composite of overdose and death.

Findings

In adjusted analyses, treatment with XR‐NTX was more likely to result in discontinuation or death by the end of follow‐up than treatment with SL‐BUP: cumulative risk 75.9% [95% confidence interval (CI) = 73.9%, 77.9%] versus 62.2% (95% CI = 61.2%, 63.2%), respectively (risk difference = 13.7 percentage points, 95% CI = 11.4, 16.0). There was minimal difference in the cumulative risk of overdose or death by the end of follow‐up: XR‐NTX 3.9% (95% CI = 3.0%, 4.8%) versus SL‐BUP 3.3% (95% CI = 2.9%, 3.7%); risk difference = 0.5 percentage points, 95% CI = –0.4, 1.5. Results were consistent across sensitivity analyses.

Conclusions

Medicaid patients in California and New Jersey, USA, receiving treatment for opioid use disorder stayed in treatment longer on sublingual buprenorphine than on extended‐release naltrexone, but the risk of overdose was similar. Most patients in this study discontinued medication within 6 months, regardless of which medication was initiated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersNaltrexoneDelayed-Action PreparationsBuprenorphineMedicaidNarcotic AntagonistsHumansAdultFemaleMaleUnited StatesYoung AdultMiddle AgedAdolescentAdministration, SublingualOpiate Substitution TreatmentCaliforniaNew JerseyCohort StudiesTreatment OutcomeDrug Overdose

Stichwörter der Autor:innen

Extended‐release naltrexoneMedicaidopioid use disorderoverdosesublingual buprenorphinetreatment retention

Substanzen

NaltrexoneDelayed-Action PreparationsBuprenorphineNarcotic Antagonists

Autor:innen und Institutionen

  • Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
  • New York State Psychiatric Institute, New York, NY, USA.
  • Department of Population Health, New York University, New York, NY, USA.
  • Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.

ORCID-Profile: Rachael K Ross, Edward V Nunes, Matisyahu Shulman, Noa Krawczyk, Kara E Rudolph

Förderung

  • NIDA NIH HHS
  • National Institute on Drug Abuse of the National Institutes of Health
  • National Institute on Drug Abuse

Zitieren

APA

Ross, R. K., Nunes, E. V., Olfson, M., Shulman, M., Krawczyk, N., Stuart, E. A., & Rudolph, K. E. (2024). Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients. Addiction. https://doi.org/10.1111/add.16630

Vancouver

Ross RK, Nunes EV, Olfson M, Shulman M, Krawczyk N, Stuart EA, et al. Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients. Addiction. 2024. doi:10.1111/add.16630

BibTeX
@article{Ross2024,
  author = {Ross, Rachael K and Nunes, Edward V and Olfson, Mark and Shulman, Matisyahu and Krawczyk, Noa and Stuart, Elizabeth A and Rudolph, Kara E},
  title = {Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients},
  journal = {Addiction},
  year = {2024},
  doi = {10.1111/add.16630}
}
Kostenlos starten →